Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegileridine vs sufentanil for postoperative analgesia and PONV in high-risk laparoscopic surgery patients
ChiCTR2600124210Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tegileridine and sufentanil in postoperative pain and postoperative nausea and vomiting (PONV) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Postoperative 24-hour pain score. Planned start May 2026; status: not yet recruiting.
02
Drugs
tegileridinesufentanil
03
Conditions
postoperative painpostoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on ChiCTR2600124210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124210.